Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Comparative Bioavailability of a Novel Solution and a Tablet Formulation of Levothyroxine.
Journal: Clinical pharmacology in drug development
Published: September 27, 2022
Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.
Journal: Nature medicine
Published: June 21, 2021
Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.
Journal: Diabetes, obesity & metabolism
Published: July 30, 2017
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study.
Journal: Diabetes care
Published: July 24, 2017
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.
Journal: Diabetes care
Published: June 29, 2017
Efficacy and risk of hypoglycemia with use of insulin glargine or comparators in patients with cardiovascular risk factors.
Journal: Postgraduate medicine
Published: June 12, 2014
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
Journal: Journal of diabetes and its complications
Published: November 03, 2013
Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.
Journal: Diabetes care
Published: May 07, 2013
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
Journal: Clinical therapeutics
Published: February 28, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026